Dicerna Pharmaceuticals, a US-based biopharmaceutical company which is developing RNA interference (RNAi)-based therapeutics, has closed a $60m series C financing. The round was led by new investor, private investment bank RA Capital, with the participation of new investors, investments firms Brookside Capital, Deerfield, and Omega Funds. All of Dicerna’s existing institutional investors also particpated: Abingworth…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
